FY2025 sbir concept clearance award for topic development of therapeutic or preventative technologies for treatment or prevention of pediatric cancers and/or rare cancers.
Active Definitive Contract Awarded Last action
- Contract number
- 75N91025C00012
- Awardee
-
Tenaci-T Therapeutics LLC UEI MTRTYVL8N717
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $297,621
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2025 Pre-Solicitation · 75N91024R00013 · Posted Mar 28, 2024
- Contract value 100% obligated
- $297,621.00 Current and potential, with all options
- Completion date 57% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 55 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Missouri City, TX 77459, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$55,000 | |
| Original award | $352,621 |
About this award
The National Cancer Institute awarded a definitive firm fixed-price contract to Tenaci-T Therapeutics LLC for $297,621 on September 17, 2025, under a total small business set-aside. The award is an FY2025 SBIR Concept Clearance Award for development of therapeutic or preventative technologies for treatment or prevention of pediatric cancers and/or rare cancers, specifically targeting FOXM1 in glioblastoma multiforme using a novel TCR-T cell therapeutic.
The originating solicitation, posted March 28, 2024, sought proposals from small business concerns for innovative and transformative technologies in therapeutic or preventative approaches, devices, diagnostics, or digital health tools addressing pediatric and rare cancers. Proposals were required to identify an anticipated product, clinical problem, and cancer type(s) to be addressed, provide initial proof-of-concept data, and develop a business model and commercialization plan. Place of performance is Missouri City, TX. The contract period extends to September 16, 2027.
Quick answers
Who was awarded contract 75N91025C00012?
75N91025C00012 was awarded to Tenaci-T Therapeutics LLC by National Cancer Institute (National Institutes of Health) on September 17, 2025.
How much is contract 75N91025C00012 worth?
The government has obligated $297,621 on 75N91025C00012.
Was contract 75N91025C00012 competed?
The extent of competition for 75N91025C00012 was full and open competition after exclusion of sources. The government received 55 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award